相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1953
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A 38-year-old pregnant woman's headaches and nausea, initially dismissed as pregnancy symptoms, were found to be caused by a giant brain tumor from metastatic stage IV melanoma. - After delivering her baby via C-section at 34 weeks, the patient underwent a second brain surgery that successfully removed the entire regrown tumor. - Immunotherapy initiated in June 2020 produced "pretty remarkable" results, with the patient declared to have no evidence of disease by October 2020. - Dr. Alicia Zhou of the Cancer Research Institute noted that immunotherapy represents a "phase shift" enabling the word "cure" for stage IV metastatic disease patients.
- The Cancer Research Institute awards the 2026 William B. Coley Award to Prof. Éric Vivier for his transformative work on natural killer cell biology and antitumor immunity. - SITC and CRI launch a new annual collaboration, with Vivier delivering the inaugural Coley Award Lecture at SITC 2026 in Phoenix, Arizona, on November 8. - Vivier's three decades of NK cell research have uncovered how these innate immune cells recognize and eliminate cancer cells, fueling a new wave of NK cell therapies. - The SITC 2026 meeting will also feature keynote speakers Ton Schumacher on T cell recognition and Catherine Wu on personalized cancer vaccines.
- OCCAM Immune, a Mount Sinai initiative, has partnered with the Cancer Research Institute to establish long-term immune monitoring across clinical trials, aiming to identify which patients benefit most from specific immunotherapies. - The collaboration will begin with a clinical trial in platinum-resistant high-grade serous ovarian cancer, analyzing 160 blood samples and tumor biopsies using RNA/DNA sequencing and immune cell mapping technologies. - This partnership combines CRI's decades of immunotherapy experience and global clinical trial access with OCCAM Immune's advanced immune profiling tools to accelerate personalized cancer treatment development. - The initiative addresses the critical challenge that immunotherapy doesn't work for all patients, seeking to understand immune system responses to therapy for more precise treatment matching.
- Coherus BioSciences has completed its strategic transformation to Coherus Oncology, reflecting its exclusive focus on proprietary innovative immuno-oncology medicines. - The company's pipeline centers on LOQTORZI (toripalimab-tpzi), the only FDA-approved PD-1 inhibitor indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma. - Two novel candidates are advancing through clinical trials: CHS-114, a selective CCR8 antibody targeting regulatory T cells, and casdozokitug, a first-in-class IL-27 antagonist showing activity across multiple cancer types. - A randomized Phase 2 study is evaluating casdozokitug combined with toripalimab and bevacizumab versus standard combination therapy in first-line advanced metastatic hepatocellular carcinoma.
- Former President Jimmy Carter's successful treatment of advanced melanoma with pembrolizumab (Keytruda) in 2015 transformed public perception and medical acceptance of immunotherapy in cancer treatment. - Carter's remarkable recovery from metastatic melanoma that had spread to four areas of his brain demonstrated the potential of immunotherapy to treat late-stage cancers effectively. - The "Carter Effect" has contributed to the approval of approximately 15 new treatments for metastatic melanoma, with immunotherapy now being a viable option for 45% of cancer patients.
